Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Helpful in Late-Stage Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Late-stage dementia brings complex challenges for families and healthcare professionals. As symptoms such as agitation, confusion, weight loss, and poor sleep intensify, some people ask whether medical cannabis could offer comfort or symptom relief. 

According to NHS and NICE guidance, there is currently no clinical evidence that cannabis-based medicinal products (CBMPs) are effective or safe for managing symptoms in late-stage dementia. 

Can medical cannabis be accessed legally for women’s health?

What The Evidence Shows 

NICE guidance on Cannabis-based Medicinal Products (NG144) states that there is insufficient robust evidence to support the use of CBMPs for behavioural or psychological symptoms of dementia at any stage. This includes late-stage disease, where vulnerability to side effects is particularly high. 

The NHS also confirms that medical cannabis is not an approved treatment for dementia in the UK. It notes that while cannabinoids such as THC and CBD are under investigation for specific medical uses, they have not been shown to improve comfort, cognition, or quality of life in advanced dementia. 

According to the Alzheimer’s Society UK, most studies of medical cannabis in dementia are small, short-term, and focused on mild to moderate stages of the disease. There is no reliable evidence that cannabinoids benefit people with severe dementia, and risks such as sedation, confusion, and falls may increase as frailty progresses. 

Ongoing research supported by Alzheimer’s Research UK and the Cochrane Dementia and Cognitive Improvement Group (2022) continues to explore whether cannabinoids might help manage agitation or distress, but so far results remain inconclusive. 

The Clinical Bottom Line 

  • Cannabis-based medicinal products are not recommended for use in late-stage dementia. 
  • NICE and NHS restrict CBMPs to formal clinical research settings only. 
  • No evidence shows benefit for comfort, agitation, or quality of life in advanced dementia. 
  • Potential harms, including confusion, sedation, and falls, increase with frailty. 
  • Families should seek medical advice on palliative or comfort-focused care options. 
  • CBMPs should not replace evidence-based dementia or palliative care. 

What This Means in Practice 

At present, medical cannabis is not recognised as a treatment for late-stage dementia. The focus of care should remain on comfort, dignity, and symptom management through established medical and palliative approaches.  

About AlleviMed 

Organisations such as AlleviMed provide educational information about how UK eligibility for medical cannabis is assessed, helping families understand the legal and clinical frameworks surrounding CBMPs, but they do not offer prescribing or treatment services. 

Takeaway 

Current evidence does not support the use of cannabis for symptom management in late-stage dementia. According to NHS, NICE, and the Alzheimer’s Society, CBMPs should only be considered within clinical research trials until stronger, long-term safety and efficacy data become available. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories